ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RZLT Rezolute Inc

3.31
0.34 (11.45%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Rezolute Inc RZLT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.34 11.45% 3.31 17:53:39
Open Price Low Price High Price Close Price Previous Close
3.06 2.98 3.38 3.31 2.97
more quote information »

Recent News

Date Time Source Heading
4/23/202407:00GLOBEPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024..
3/11/202416:03EDGAR2Form 8-K - Current report
3/11/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202406:30GLOBERezolute Reports Validation of the Potential Use of RZ358..
2/27/202407:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/22/202416:00EDGAR2Form 8-K - Current report
2/21/202410:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/13/202416:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202415:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2/13/202415:10EDGAR2Form 8-K - Current report
2/13/202415:05GLOBERezolute Reports Second Quarter Fiscal 2024 Results and..
1/29/202416:15EDGAR2Form 8-K - Current report
1/25/202411:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/25/202411:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/25/202411:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/25/202411:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/24/202407:00GLOBERezolute Expands Leadership Team with Appointment of Daron..
1/23/202407:00GLOBERezolute Receives Innovation Passport Designation from the..
12/14/202315:01EDGAR2Form 8-K - Current report
12/14/202307:00GLOBERezolute Initiates Phase 3 Clinical Study for RZ358 in..
12/13/202307:00GLOBERezolute Completes Enrollment of its Phase 2 Study in..
11/29/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
11/22/202316:16EDGAR2Form S-3/A - Registration statement under Securities Act of..
11/22/202315:35EDGAR2Form 8-K - Current report
11/17/202307:00GLOBERezolute to Participate in BTIG’s 3rd Annual Ophthalmology..
11/15/202308:08EDGAR2Form S-3 - Registration statement under Securities Act of..
11/13/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/13/202315:13EDGAR2Form 8-K - Current report
11/13/202315:05GLOBERezolute Reports First Quarter Fiscal 2024 Results
10/18/202315:30EDGAR2Form 8-K - Current report
10/17/202307:00GLOBERezolute Receives Priority Medicines (PRIME) Eligibility..
10/13/202315:47EDGAR2Form 8-K - Current report
10/13/202315:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/11/202307:00GLOBERezolute Announces Further Evidence of RZ358’s Efficacy in..
9/14/202315:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
9/14/202315:10EDGAR2Form 8-K - Current report
9/14/202315:05GLOBERezolute Reports Full Year Fiscal 2023 Results and..
9/06/202306:00GLOBERezolute to Participate in Upcoming Investor Conferences in..
7/06/202310:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
6/27/202315:05GLOBERezolute to Initiate a Pivotal Phase 3 Study of RZ358 in..
5/11/202315:05GLOBERezolute Reports Third Quarter Fiscal 2023 Results and..

Your Recent History

Delayed Upgrade Clock